Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Erik Stroes, John R Guyton, Norman Lepor, Fernando Civeira, Daniel Gaudet, Gerald F Watts, Marie T Baccara-Dinet, Guillaume Lecorps, Garen Manvelian, Michel Farnier, ODYSSEY CHOICE II Investigators

    Research output: Contribution to journalArticlepeer-review

    64 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study'. Together they form a unique fingerprint.

    Medicine & Life Sciences